Perinatal exposure to the thyroperoxidase inhibitors methimazole and amitrole perturbs thyroid hormone system signaling and alters motor activity in rat offspring. (1st January 2022)

• Record Type: Journal Article
• Authors: Ramhøj, Louise; Svingen, Terje; Frädrich, Caroline; Rijntjes, Eddy; Wirth, Eva K.; Pedersen, Katrine; Köhrle, Josef; Axelstad, Marta
• Is Part Of: Toxicology letters. Volume 354(2022)
• Page Start: 44
• Page End: 55
• Publication Date: 2022-01-01
• Subjects: Thyroid hormone -- Thyroperoxidase -- Developmental neurotoxicity -- Endocrine disruption -- Behavior -- Hypothyroidism -- Development -- HPT-axis -- Thyroxine; Toxicology -- Periodicals; 363.179
• DOI: 10.1016/j.toxlet.2021.10.010
• Languages: English
• ISSNs: 0378-4274

Abstract

Graphical abstract: Highlights: TPO inhibitors MMI and amitrole elicit similar disruptions of the thyroid hormone system. MMI and amitrole perturb thyroid hormone dependent rat brain development via TPO inhibition. MMI and amitrole reduce expression of thyroid hormone-sensitive genes in cerebral cortex. MMI and amitrole alter motor activity of perinatally exposed rat offspring. Abstract: Disruption of the thyroid hormone system during development can impair brain development and cause irreversible damage. Some thyroid hormone system disruptors act by inhibiting the thyroperoxidase (TPO) enzyme, which is key to thyroid hormone synthesis. For the potent TPO-inhibiting drug propylthiouracil (PTU) this has been shown to result in thyroid hormone system disruption and altered brain development in animal studies. However, an outstanding question is which chemicals beside PTU can cause similar effects on brain development and to what degree thyroid hormone insufficiency must be induced to be able to measure adverse effects in rats and their offspring. To start answering these questions, we performed a perinatal exposure study in pregnant rats with two TPO-inhibitors: the drug methimazole (MMI) and the triazole herbicide amitrole. The study involved maternal exposure from gestational day 7 through to postnatal day 22, to MMI (8 and 16 mg/kg body weight/day) or amitrole (25 and 50 mg/kg body weight/day). Both MMI and amitrole reduced serum T4 concentrations in a dose-dependent manner in dams and offspring, with a strong activation of the hypothalamic-pituitary-thyroid axis. This reduction in serum T4 led to decreased thyroid hormone-mediated gene expression in the offspring's brains and caused adverse effects on brain function, seen as hyperactivity and decreased habituation in preweaning pups. These dose-dependent effects induced by MMI and amitrole are largely the same as those observed with PTU. This demonstrates that potent TPO-inhibitors can induce effects on brain development in rats and that these effects are driven by T4 deficiency. This knowledge will aid the identification of TPO-inhibiting thyroid hormone system disruptors in a regulatory context and can serve as a starting point in search of more sensitive markers of developmental thyroid hormone system disruption.